Incredibly, an Australian company called ResApp Health Limited has developed a smartphone app that can detect COVID. The company, a spinoff from research conducted at the University of Queensland, says their app "records a patient's cough on a smartphone and analyses sounds and simple symptoms, such as a runny nose, to diagnose and measure the severity of a range of chronic and acute diseases."

The app was incepted prior to the pandemic, and was originally developed to detect asthma, pneumonia, bronchiolitis, croup and chronic obstructive pulmonary disease; the team subsequently added COVID to the list, finding that they could accurately detect 92% of COVID cases.

"This is one of the most exciting Australian biotech deals to come out of university research,"said Dr. Dean Moss, CEO of UniQuest, the University of Queensland's licensing and commercialization company. The deal he's referring to: Pfizer acquired ResApp Health Limited for a whopping AUD $179 million (USD $116 million)!